A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

(2011) A. Alvarez-Larran et al.   BLOOD

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study

(2011) H. Frederiksen et al.   BLOOD

Higher risk of primary cancers after polycythaemia vera and vice versa

(2011) Mahdi Fallah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors

(2011) S. Bhatia   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase

(2011) Jill O. Fuss et al.   DNA REPAIR

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

(2011) Jean-Jacques Kiladjian et al.   JOURNAL OF CLINICAL ONCOLOGY

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

(2010) C. Nielsen et al.   HAEMATOLOGICA

Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

(2009) A. M. Vannucchi et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients

(2009) A Pardanani et al.   LEUKEMIA

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden

(2008) O. Landgren et al.   BLOOD

DNA Repair Gene XPD Polymorphisms and Cancer Risk: A Meta-analysis Based on 56 Case-Control Studies

(2008) F. Wang et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

(2008) F. Passamonti et al.   HAEMATOLOGICA

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA